New drug aims to calm severe eczema without steroids

NCT ID NCT07690371

Recruiting now Disease control Sponsor: Nektar Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear or nearly clear the skin and reduce eczema severity over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rezpegaldesleukin (NKTR-358)
What this could lead to: If successful, this could provide a new treatment option for people with moderate-to-severe atopic dermatitis, potentially reducing skin inflammation and improving quality of life.
What could go wrong: This is a Phase 3 trial, but the drug is still experimental. It may not work better than placebo, and side effects are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ATOPIC DERMATITIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nektar Investigative Site
RECRUITING

St. Petersburg, Florida, 33714, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.